Keros Therapeutics (NASDAQ:KROS) Stock Price Down 2.7% on Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS) traded down 2.7% during trading on Tuesday after Truist Financial lowered their price target on the stock from $100.00 to $43.00. Truist Financial currently has a buy rating on the stock. Keros Therapeutics traded as low as $16.63 and last traded at $16.65. 211,223 shares were traded during trading, a decline of 57% from the average session volume of 487,966 shares. The stock had previously closed at $17.12.

A number of other analysts have also weighed in on the company. Oppenheimer lowered their target price on Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, December 16th. Wells Fargo & Company upped their target price on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Bank of America lowered their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Finally, BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KROS. FMR LLC grew its position in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after buying an additional 179,374 shares during the period. Alkeon Capital Management LLC grew its holdings in Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after purchasing an additional 298,694 shares during the period. Darwin Global Management Ltd. increased its stake in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after purchasing an additional 89,952 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares during the period. Finally, Holocene Advisors LP raised its holdings in Keros Therapeutics by 22.5% in the third quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the period. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

The company has a market capitalization of $676.87 million, a P/E ratio of -3.21 and a beta of 1.20. The business’s 50-day moving average price is $53.23 and its two-hundred day moving average price is $51.17.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the company posted ($1.33) EPS. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. Research analysts expect that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.